Skip to main content

Table 4 Overview of published results on hypofractionated stereotactic radiotherapy (HFSRT) in patients with recurrent malignant glioma (RT: radiotherapy).

From: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

authors patient number single dose (Gy) total dose (Gy) median tumor volume (ml) chemo-therapy overall survival (median) surgery for toxicity prognostic factors comment
Shepherd et al., 1997 [4] 29 ("high-grade astrocy-toma") 5 (daily) 20–50 24 (3–93) -- 10.7 months 6% initial low-grade histology associated with longer survival 36% steroid dependent toxicity (increased risk >40 Gy)
Glass et al., 1997 [6] 20 (7 grade III, 13 grade IV) 3.5–6 (twice / week) 35–42 14 (2–122) cisplatin 40 mg/m2 weekly 12.7 months 15% pre-dominant necrosis on re-operation -- 40% treated within 10 weeks of first RT series for ("potential") progression
Hudes et al., 1999 [5] 19 (glio-blastoma) 3–3.5 (daily) 24–35 13 (1–48) -- 10.5 months 0% "minor response" on imaging associated with ≥30 Gy and ≤20 ml recurrent or persistent tumors treated, median interval between completion of RT and HFSRT only 3.1 months
Lederman et al., 2000 [7] 88 (glio-blastoma) 4–9 (weekly) 18–36 32.7 (2–150) paclitaxel 120 mg/m2 (median) weekly 7 months 8% necrosis only at re-operation volume ≥30 ml associated with longer survival median time from diagnosis to HFSRT only 6.5 months
Voynov et al., 2002 [8] 10 (5 WHO grade III, 5 grade IV) 5 30 34.7 -- 10.1 months ? -- stereotactic intensity-modulated radiotherapy (IMRT) used
present series 19 (5 WHO grade III, 14 grade IV) 4–10 (daily) 20–30 15 (4–70) -- 9.3 months 0% WHO grade IV and <30 Gy associated with short survival median interval post-OP RT to HFSRT 19 months